ATE390414T1 - Arzneimittelwirkstoffe mit zwei kovalent verknüpften wirkstoffgruppen (natriumkanalblocker/p2y2 rezeptor agonist) zur behandlung von schleimhäuten - Google Patents

Arzneimittelwirkstoffe mit zwei kovalent verknüpften wirkstoffgruppen (natriumkanalblocker/p2y2 rezeptor agonist) zur behandlung von schleimhäuten

Info

Publication number
ATE390414T1
ATE390414T1 AT00948820T AT00948820T ATE390414T1 AT E390414 T1 ATE390414 T1 AT E390414T1 AT 00948820 T AT00948820 T AT 00948820T AT 00948820 T AT00948820 T AT 00948820T AT E390414 T1 ATE390414 T1 AT E390414T1
Authority
AT
Austria
Prior art keywords
sodium channel
channel blocker
receptor agonist
mucous
measures
Prior art date
Application number
AT00948820T
Other languages
English (en)
Inventor
Richard Boucher
Original Assignee
Univ North Carolina
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ North Carolina filed Critical Univ North Carolina
Application granted granted Critical
Publication of ATE390414T1 publication Critical patent/ATE390414T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/12—Mucolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D241/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
AT00948820T 1999-07-19 2000-07-19 Arzneimittelwirkstoffe mit zwei kovalent verknüpften wirkstoffgruppen (natriumkanalblocker/p2y2 rezeptor agonist) zur behandlung von schleimhäuten ATE390414T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14447999P 1999-07-19 1999-07-19
US09/618,978 US6475509B1 (en) 1999-07-19 2000-07-19 Covalent conjugates of sodium channel blockers and active compounds

Publications (1)

Publication Number Publication Date
ATE390414T1 true ATE390414T1 (de) 2008-04-15

Family

ID=26842041

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00948820T ATE390414T1 (de) 1999-07-19 2000-07-19 Arzneimittelwirkstoffe mit zwei kovalent verknüpften wirkstoffgruppen (natriumkanalblocker/p2y2 rezeptor agonist) zur behandlung von schleimhäuten

Country Status (18)

Country Link
US (3) US6475509B1 (de)
EP (1) EP1196396B1 (de)
JP (1) JP2004513870A (de)
KR (1) KR20020038694A (de)
AT (1) ATE390414T1 (de)
AU (1) AU774865B2 (de)
CA (1) CA2378181A1 (de)
CY (1) CY1108117T1 (de)
DE (1) DE60038449T2 (de)
DK (1) DK1196396T3 (de)
ES (1) ES2304352T3 (de)
HK (1) HK1047091B (de)
IS (1) IS6222A (de)
MX (1) MXPA02000684A (de)
NO (1) NO20020242L (de)
NZ (1) NZ516595A (de)
PT (1) PT1196396E (de)
WO (1) WO2001005773A1 (de)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4969002B2 (ja) * 1999-06-08 2012-07-04 ユニバーシテイ・オブ・アイオワ・リサーチ・フアウンデーシヨン ｒＡＡＶ形質導入を増加するための化合物および方法
US7241447B1 (en) * 1999-10-07 2007-07-10 University Of Iowa Research Foundation Adeno-associated virus vectors and uses thereof
US6858615B2 (en) 2002-02-19 2005-02-22 Parion Sciences, Inc. Phenyl guanidine sodium channel blockers
US6858614B2 (en) 2002-02-19 2005-02-22 Parion Sciences, Inc. Phenolic guanidine sodium channel blockers
US6903105B2 (en) 2003-02-19 2005-06-07 Parion Sciences, Inc. Sodium channel blockers
WO2004089423A2 (en) * 2003-03-31 2004-10-21 University Of Iowa Research Foundation Pharmico-gene theraphy of epithelial sodium channel associated disoders
CA2534568A1 (en) * 2003-08-18 2005-03-24 Parion Sciences, Inc. Aliphatic pyrazinoylguanidine sodium channel blockers
AU2004266704B2 (en) * 2003-08-18 2012-02-23 Parion Sciences, Inc. Capped pyrazinoylguanidine sodium channel blockers
EP1670474A4 (de) * 2003-08-18 2008-08-06 Parion Sciences Inc Cyclische pyrazinoylguanidine als natriumkanalblocker
WO2006101629A2 (en) * 2005-02-17 2006-09-28 Vertex Pharmaceuticals Incorporated SODIUM CHANNEL PROTEIN TYPE III α-SUBUNIT SPLICE VARIANT
US7972813B2 (en) * 2005-09-30 2011-07-05 Vertex Pharmaceuticals Incorporated Tetrodotoxin-resistant sodium channel alpha subunit
US20080200408A1 (en) * 2005-09-30 2008-08-21 Mccormack Kenneth Deletion mutants of tetrodotoxin-resistant sodium channel alpha subunit
GB0526240D0 (en) * 2005-12-22 2006-02-01 Novartis Ag Organic compounds
EP2019964A2 (de) * 2006-04-28 2009-02-04 University of Iowa Research Foundation Verfahren und verbindungen zur modulation der parvovirusübertragung von säugerzellen oder zur änderung von virusinfektionen verfahren zur identifizierung eines viralen rezeptors oder co-rezeptors
US20110195973A1 (en) * 2006-06-09 2011-08-11 Parion Sciences, Inc. Cyclic substituted pyrazinoylguanidine sodium channel blockers possessing beta agonist activity
AU2007294547A1 (en) * 2006-09-07 2008-03-13 Parion Sciences, Inc. Methods of enhancing mucosal hydration and mucosal clearance by treatment with sodium channel blockers and osmolytes
WO2008031048A2 (en) * 2006-09-07 2008-03-13 Parion Sciences, Inc. Enhanced mucosal hydration and mucosal clearance by treatment with sodium channel blockers and osmolytes
EP2332933A1 (de) 2007-05-07 2011-06-15 Novartis AG Epithelial Natrium-Kanal Inhibitoren
WO2018129556A1 (en) 2017-01-09 2018-07-12 Ardelyx, Inc. Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
CN103819403B (zh) 2008-12-31 2017-01-04 阿德利克斯公司 用于治疗与体液潴留或盐超负荷有关的病症和胃肠道病症的化合物和方法
AR086745A1 (es) 2011-06-27 2014-01-22 Parion Sciences Inc 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil)carbamimidoil)pirazina-2-carboxamida
NO2773633T3 (de) 2011-11-02 2017-12-30
US10376481B2 (en) 2012-08-21 2019-08-13 Ardelyx, Inc. Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
RU2015107019A (ru) 2012-08-21 2016-10-10 Эрделикс Инк. Соединения и способы для ингибирования nhe-опосредованного антипорта в лечении расстройств, ассоциированных с задержкой жидкости или солевой перегрузкой и заболеваний желудочно-кишечного тракта
HUE032891T2 (hu) 2012-12-17 2017-11-28 Parion Sciences Inc Klórpirazin-karboxamid-származékok nem kielégítõ nyálkahártya-hidratáció által elõsegített megbetegedések kezelésére
RU2671976C2 (ru) 2012-12-17 2018-11-08 Пэрион Сайенсиз, Инк. Соединения 3,5-диамино-6-хлор-n-(n-(4-фенилбутил)карбамимидоил)пиразин-2-карбоксамида
CN105392483B (zh) 2013-04-12 2019-03-15 阿德利克斯公司 用于抑制磷酸盐转运的nhe3结合化合物和方法
CA2915633A1 (en) 2013-07-02 2015-01-08 The California Institute For Biomedical Research Compounds for treatment of cystic fibrosis
CA2920856C (en) 2013-08-09 2026-03-03 Ardelyx, Inc. Ph modulating compounds for inhibiting gastrointestinal phosphate uptake
US9102633B2 (en) 2013-12-13 2015-08-11 Parion Sciences, Inc. Arylalkyl- and aryloxyalkyl-substituted epithelial sodium channel blocking compounds
CN107405505A (zh) * 2015-01-07 2017-11-28 加州生物医学研究所 用于治疗囊性纤维化的化合物
AU2016252864B2 (en) 2015-04-24 2021-10-14 Duke University Metal complexes with bisphosphonate or pyrophosphate useful as imaging agents
WO2017139381A1 (en) 2016-02-08 2017-08-17 University Of Iowa Research Foundation Methods to produce chimeric adeno-associated virus/bocavirus parvovirus
WO2017155973A1 (en) 2016-03-07 2017-09-14 University Of Iowa Research Foundation Aav-mediated expression using a synthetic promoter and enhancer
US12173305B2 (en) 2016-05-26 2024-12-24 University Of Iowa Research Foundation cis and trans requirements for terminal resolution of human bocavirus 1
EA201991676A1 (ru) 2017-01-09 2020-01-30 Арделикс, Инк. Ингибиторы nhe-опосредованного антипорта
KR20240090875A (ko) 2017-01-09 2024-06-21 알데릭스, 인코포레이티드 위장관 장애를 치료하는 데 유용한 화합물
US11142775B2 (en) 2017-01-13 2021-10-12 University Of Iowa Research Foundation Bocaparvovirus small noncoding RNA and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL299931A (de) 1962-10-30
US5292498A (en) 1991-06-19 1994-03-08 The University Of North Carolina At Chapel Hill Method of treating lung disease with uridine triphosphates
US5656256A (en) 1994-12-14 1997-08-12 The University Of North Carolina At Chapel Hill Methods of treating lung disease by an aerosol containing benzamil or phenamil
US5635160A (en) * 1995-06-07 1997-06-03 The University Of North Carolina At Chapel Hill Dinucleotides useful for the treatment of cystic fibrosis and for hydrating mucus secretions
US5837861A (en) * 1997-02-10 1998-11-17 Inspire Pharmaceuticals, Inc. Dinucleotides and their use as modulators of mucociliary clearance and ciliary beat frequency
US6264975B1 (en) * 1998-10-20 2001-07-24 The University Of North Carolina At Chapel Hill Methods of hydrating mucosal surfaces

Also Published As

Publication number Publication date
US6613345B2 (en) 2003-09-02
KR20020038694A (ko) 2002-05-23
WO2001005773A8 (en) 2001-06-14
US20020165239A1 (en) 2002-11-07
NO20020242L (no) 2002-03-19
ES2304352T3 (es) 2008-10-16
US6475509B1 (en) 2002-11-05
US6607741B2 (en) 2003-08-19
EP1196396A1 (de) 2002-04-17
MXPA02000684A (es) 2003-07-21
WO2001005773A1 (en) 2001-01-25
CA2378181A1 (en) 2001-01-25
JP2004513870A (ja) 2004-05-13
HK1047091B (en) 2008-07-04
NZ516595A (en) 2003-07-25
DE60038449T2 (de) 2009-04-09
NO20020242D0 (no) 2002-01-16
PT1196396E (pt) 2008-05-14
CY1108117T1 (el) 2014-02-12
US20020158255A1 (en) 2002-10-31
DK1196396T3 (da) 2008-07-14
HK1047091A1 (en) 2003-02-07
IS6222A (is) 2002-01-08
AU6226200A (en) 2001-02-05
EP1196396B1 (de) 2008-03-26
AU774865B2 (en) 2004-07-08
DE60038449D1 (de) 2008-05-08

Similar Documents

Publication Publication Date Title
DE60038449D1 (de) Arzneimittelwirkstoffe mit zwei kovalent verknüpften wirkstoffgruppen (natriumkanalblocker/p2y2 rezeptor agonist) zur behandlung von schleimhäuten
GEP20043269B (en) Purine Derivatives, Method for Their Production and Composition Containing the Same
EP1428821A8 (de) Piperidin-4-ylamine mit analgetischer Wirksamkeit
MY115662A (en) Novel compounds with analgesic effect
SE8804629D0 (sv) New therapeutically active compounds
BG103947A (en) Derivatives of 9-oxymerythromycin
MY123354A (en) 4"-substituted-9-deoxo-9a-aza-9a-homoerythromycin a derivatives
CY1107850T1 (el) Παραγωγα θειαδιαζολυλοπιπεραζiνης mε χρησιμοτητα στην αποτροπη ή στην αγωγη εναντι tου αλγους
EE200100558A (et) Triarüülhappe derivaat, seda sisaldav farmatseutiline kompositsioon ja ühendi raviotstarbeline kasutamine
AP9701041A0 (en) Pyridylpyrrole compounds.
MY133647A (en) Substituted quinoline-2-carboxamides, their preparation and their use as pharmaceuticals, and intermediates
BG103268A (en) Propionic acid derivatives and their application
UA70298A (uk) Похідні с-4"-заміщених макролідів, спосіб їх одержання, проміжні сполуки, фармацевтична композиція та спосіб лікування бактеріальної інфекції або протозойної інфекції
AU669122B2 (en) New pyrazine derivatives, their preparation and their use
AP9801378A0 (en) 9-amino-3- keto erythromycin derivatives.
GEP20033079B (en) Pharmaceutical Compositions for Treatment of Diseases Caused by Estrogens Deficiency
PT992509E (pt) Novos derivados macrolidos
BR9611871A (pt) Diaminopirimidinas composições farmacêuticas contendo as mesmas e seu uso como antibactericidas
TW367326B (en) Pyrimidine derivative, process for the preparation thereof and a pharmaceutical composition containing same
IT1256320B (it) Derivati eterociclici
MY129946A (en) Compound with gastric acid inhibitory effect and process for its preparation.
SE9504662D0 (sv) New compounds
EP1027051A4 (de) Antithrombotische mittel
AP9801235A0 (en) Erythromycin derivatives.
DK0541726T3 (da) Vækstfaktorsammensætninger, fremstilling og anvendelse

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1196396

Country of ref document: EP